Pertuzumab - Wikipedia, the free encyclopedia
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors".
HER2/neu - Wikipedia, the free encyclopedia
Another monoclonal antibody, Pertuzumab, which inhibits dimerization of HER2 and HER3 receptors, is in advanced clinical trials. The expression of HER2/ERBB2 protein is regulated by ...
Roche - Pertuzumab with Herceptin shows impressive results in women ...
Basel, 30 May 2008 Pertuzumab with Herceptin shows impressive results in women with advanced HER2-positive breast cancer New data from a Phase II trial presented at the American ...
Pertuzumab (Omnitarg™) and Herceptin® (Trastuzumab) Effective for ...
Pertuzumab (Omnitarg™) and Herceptin® (Trastuzumab) Effective for Metastatic HER2-Positive Breast Cancer. Researchers involved in an international study have reported that the ...
Pertuzumab Phase II results in advanced prostate cancer » PSA Rising ...
Pertuzamab is a new targeted anti-cancer drug that blocks the human epidermal growth factor (HER) receptor family. It belongs to the class of drugs called monoclonal antibodies ...
Genentech: Newsroom: Press Releases: News Release January 4, 2007
Genentech News Release - Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab in Combination with Gemcitabine for Advanced Ovarian Cancer
Pertuzumab monotherapy following trastuzumab-based treatment: Activity ...
Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. - ASCO - The American Society of ...
Roche Holding AG Says Herceptin With Pertuzumab "Impressive" - News ...
Roche Holding AG Says Herceptin With Pertuzumab "Impressive" 5/30/2008 Basel, 30 May 2008. New data from a Phase II trial presented at the American Society of Clinical Oncology ...
A Study of Pertuzumab in Combination With Herceptin in Patients With ...
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive ...
